|
Thank you for your role in supporting access to therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process. |
|
Federal Allocations
Week of December 12th:
mAbs Allocation Cycle
-
Evusheld (monthly): 2,340
Oral antivirals - Weekly (one week cycle)
-
Lagevrio (molnupiravir): 211
-
Paxlovid: 1,180
-
Renal Paxlovid: 105
|
|
Important Updates
Bebtelovimab (No longer authorized)
-
NEW! FDA announced Bebtelovimab is no longer authorized for use in any US region see below for more information.
The Oregon Health Authority has partnered with Color Health to offer free telehealth visits in Oregon. To learn more, please visit our COVID-19 Treatments page
Evusheld
-
Evusheld EUA fact sheet
- NEW! Evusheld loses neutralization potency against BA.4.6 and potentially also against BF.7, BA.275.2 and BQ subvariants. See fact sheet for more information
- Evusheld shelf life extensions
- Evusheld re-dosing
-
The AstraZeneca Call Center remains available should you have questions regarding the updated dosing guidance and/or the shelf-life extension for Evusheld. The AstraZeneca Call Center can be reached at 1-800-236-9933
-
Evusheld can now be directly ordered in small quantities for individual providers through this form: OrderEvusheld.com
-
Evusheld is now available at some Federally Registered Pharmacy Partners for patients with an Evusheld prescription
Convalescent Plasma
The use of COVID-19 Convalescent Plasma (CCP) in patients who are immunocompromised:
- There is currently insufficient evidence for the Panel to recommend either for or against the use of high-titer CCP for the treatment of COVID-19 in hospitalized or non-hospitalized patients who are immunocompromised.
- Some Panel members would use CCP to treat an immunocompromised patient with significant symptoms attributable to COVID-19 and with signs of active SARS-CoV-2 replication and who is having an inadequate response to available therapies. In these cases, clinicians should attempt to obtain high-titer CCP from a vaccinated donor who recently recovered from COVID-19 likely caused by a SARS-CoV-2 variant similar to the variant causing the patient’s illness (HHS, December 2, 2022).
Veklury (Commercial Product)
-
FDA approved expanded use of Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for treatment of mild-to-moderate COVID-19 disease (Jan 21, 2022), including:
-
Adults and pediatric patients 28 days of age and older and weighing at least 3kg with a positive result of direct SARS-CoV-2 viral testing AND
-
Individuals who are not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death
-
The treatment course of Veklury (remdesivir) should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset. The recommended total duration of treatment for non-hospitalized patients is 3 days
-
Veklury Product Information
-
Veklury Fact Sheet
-
To purchase Veklury, please visit: Gilead Pharmaceuticals
-
Veklury is available through multiple distributors. For additional information regarding purchasing or how to access Veklury (remdesivir), email remdesivir@amerisourcebergen.com, or reach out directly to your AmerisourceBergen, Cardinal, or McKesson representative
Additional Resources
-
The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) sites and where to send prescriptions to be filled
-
Please check the locator periodically as sites continue to be added
-
The locator's accuracy relies on providers reporting inventory and utilization
-
If you are needing additional assistance with provider registration, ordering, or any other process related to therapeutics, please fill out the Office Hours Request Form to select office hour availability
-
For additional clinical guidance, please review the Multnomah County Clinician Alert and the University of Liverpool COVID-19 Drug Interaction tool
-
For additional guidance on the new ordering process, cadence, and reporting utilization, please review our Provider Operations Manual
-
For additional federal updates, shelf life extensions, and more, please visit the ASPR webpage
|
|
 Placing Requests
Product Case Size
Each product has a specific case size and is outlined below. When ordering, please consider the case size and order accordingly to ensure OHA can fulfill your requests properly.
- Evusheld - 12 courses
-
Bebtelovimab - 5 cases
-
Paxlovid - 20 courses
-
Renal Paxlovid - 5 courses
-
Lagevrio (molnupiravir) - 15 courses
Cadence
-
Monday - HHS notifies Oregon of our total therapeutics allotment.
NOTE: HHS informs Oregon of Evusheld’s total allotment monthly, every 4th Monday
-
Wednesday - Orders received by 11:59 p.m. will be allocated for the current week
-
Thursday/Friday - OHA staff will review the requests, determine allotments for each requesting site, and process via the Health Partner Ordering Portal (HPOP) by Friday.
NOTE: AmerisourceBergen anticipates shipping the products within 3-5 days of order submission.
Utilization reporting
Utilization reporting is a key component that HHS takes into consideration when determining each state’s allotment. Therefore, it is crucial that each site report their utilization twice a week on Mondays and Thursdays by 11:59pm, including for any product redistributed to other sites. Under-utilization in HPoP and under-reporting will affect Oregon’s future allocations.
Track your shipment
Once your packages are shipped by Amerisource Bergen, you can track them using Track My Shipment Tool.
For oral antivirals shipment tracking, please visit your HPOP account and reference "Therapeutic Shipping."
Thank you,
Oregon Health Authority
|
|
|
|
